PROTAGONIST THERAPEUTICS INC (PTGX) Stock News
NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD
PTGX Latest News, Press Relases and Analysis
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the second qua...
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
The 3 Best Biotech Stocks to Buy in June 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.
3 Growth Stocks No One Is Watching (But They Should Be)
While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential.
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Protagonist Therapeutics will join the SmallCap 600 on Wednesday.
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the first quar...
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
